Skip to content

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
AbbVie logo
AbbVieABBV
0.5×0.0×
Immunovant, Inc. logo
Immunovant, Inc.IMVT
0.0×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
0.0×
Summit Therapeutics logo
Summit TherapeuticsSMMT
0.0×

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Calculated from Apogee Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s debt-to-assets?
Apogee Therapeutics, Inc. (APGE) reported debt-to-assets of 0× in Q1 2026.
How has Apogee Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Apogee Therapeutics, Inc.'s debt-to-assets decreased by 62.4% year-over-year, from 0× to 0×.
What is the long-term trend for Apogee Therapeutics, Inc.'s debt-to-assets?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s debt-to-assets has grown at a 37.1% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.